Clinical Trials Directory

Trials / Unknown

UnknownNCT02319980

The Adult Hemorrhagic Moyamoya Surgery Study

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
360 (estimated)
Sponsor
Huashan Hospital · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to investigate whether extracranial-intracranial(EC-IC) bypass surgery could prevent rebleeding and improve neurological function in adult moyamoya with hemorrhagic onset.

Detailed description

About one half of adult moyamoya patients present with hemorrhagic onset.As the bleeding events are potentially fatal, it often lead to particularly poor prognosis.However, the natural history is still poorly understood.Although the rebleeding rate is known to be extremely high,no effective therapeutic method has been established based on a worldwide consensus. The recently published Japanese Adult Moyamoya(JAM) Trial, which is the first prospective,randomized,controlled trial focused on hemorrhagic moyamoya,showed that direct bypass surgery could reduce the rebleeding rate and improve the prognosis.However,the result was statistically marginal with a small sample size and most importantly,it failed to assess the neurological function.The effect of bypass surgery on functional outcome was uncertain. Therefore,the AHMSS study in China is designed to compare the efficacy and safety of EC-IC bypass surgery with conservative treatment in adult moyamoya patients with hemorrhagic onset by comprehensive assessment of rebleeding rate, neurological function.

Conditions

Interventions

TypeNameDescription
PROCEDUREExtracranial-intracranial bypass surgeryAll participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)

Timeline

Start date
2015-05-01
Primary completion
2023-05-01
Completion
2023-05-01
First posted
2014-12-19
Last updated
2016-02-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02319980. Inclusion in this directory is not an endorsement.